Results 41 to 50 of about 6,034 (173)

T‐Cell Biology in the Female Reproductive Tract: Relevance to HIV Infection

American Journal of Reproductive Immunology, Volume 95, Issue 6, June 2026.
ABSTRACT Worldwide, most HIV infections occur across a mucosal surface during sexual contact, with women accounting for nearly half of reported new HIV infections across the globe in 2024. Most new infections in women and girls are believed to involve transmission across mucosal surfaces of the lower reproductive tract, which includes the vagina and ...
Barbara L. Shacklett, Ramatoulaye H. Ouattara, April L. Ferre   +2 more
wiley   +1 more source

Prevotella bivia Influences Antiretroviral Pharmacokinetics and Viral Replication in an Ex Vivo Vaginal Tissue Model

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT The vaginal microbiome plays a complex role in tenofovir's mucosal pharmacology. While the relative contribution of systemic versus local concentrations to PrEP PK/PD is an ongoing debate, the development of effective HIV prevention requires an understanding of events at the site of transmission.
Alyssa M. Lantz, Lindsey B. Collins, Elizabeth B. Hirsch, Christopher Staley, Melanie R. Nicol   +4 more
wiley   +1 more source

Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse   +5 more
wiley   +1 more source

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth

Haematologica, 2019
Classic Hodgkin lymphoma tumor cells express a functional CCR5 receptor, and tumor tissues express high CCL5 levels, suggesting that CCL5-CCR5 signaling is involved in tumor-microenvironment formation and tumor growth.
Naike Casagrande, Cinzia Borghese, Lydia Visser, Maurizio Mongiat, Alfonso Colombatti, Donatella Aldinucci   +5 more
doaj   +1 more source

Neurocognition with maraviroc compared with tenofovir in HIV [PDF]

AIDS, 2016
To determine whether maraviroc (MVC) has unique neurocognitive benefits in the context of initial antiretroviral therapy (ART).
Kevin R, Robertson, Sachiko, Miyahara, Anthony, Lee, Todd T, Brown, Ellen S, Chan, Baiba, Berzins, David, Rusin, Joseph J, Eron, Babafemi O, Taiwo   +8 more
openaire   +2 more sources

Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

PLoS ONE, 2013
BackgroundImmunological non-responders (INRs) lacked CD4 increase despite HIV-viremia suppression on HAART and had an increased risk of disease progression.
Stefano Rusconi, Paola Vitiello, Fulvio Adorni, Elisa Colella, Emanuele Focà, Amedeo Capetti, Paola Meraviglia, Clara Abeli, Stefano Bonora, Marco D'Annunzio, Antonio Di Biagio, Massimo Di Pietro, Luca Butini, Giancarlo Orofino, Manuela Colafigli, Gabriella d'Ettorre, Daniela Francisci, Giustino Parruti, Alessandro Soria, Anna Rita Buonomini, Chiara Tommasi, Silvia Mosti, Francesca Bai, Silvia Di Nardo Stuppino, Manuela Morosi, Marco Montano, Pamela Tau, Esther Merlini, Giulia Marchetti   +28 more
doaj   +1 more source

HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab

Journal of Medical Virology, Volume 98, Issue 4, April 2026.
ABSTRACT The study assessed the phenotypic susceptibility of non group‐M human immunodeficiency virus type 1 (HIV‐1/non‐M) clinical isolates to ibalizumab, the first‐in‐class long‐acting CD4‐directed post‐attachment inhibitor. Thirty isolates were tested: 1 HIV‐1/M (reference strain BRU.HXB2), 2 HIV‐1/N, 26 HIV‐1/O and 1 HIV‐1/P.
Lucie Poisson, Quentin Le Hingrat, Fanny Lermechain, Fabienne Tombette, Henri Jullien, Jean‐Christophe Plantier, Elodie Alessandri‐Gradt   +6 more
wiley   +1 more source

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Malaria Journal, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Ivanovic Jelena, Gallo Anna L, D'Avolio Antonio, Tempestilli Massimo, Bellagamba Rita, Tommasi Chiara, Nicastri Emanuele, Pucillo Leopoldo P, Narciso Pasquale   +8 more
doaj   +1 more source

Druggable genome‐wide Mendelian randomization analysis identifies potential treatment targets in vascular dementia

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 2, April/June 2026.
Abstract BACKGROUND There are currently no US Food and Drug Administration‐approved treatments for vascular dementia (VaD). Genome‐wide approaches have successfully identified druggable targets and treatments for various disorders. In this study, we performed druggable genome‐wide two‐sample Mendelian randomization (2SMR) analysis to identify possible ...
Matthew J. Lennon, Ying Xu, Anbupalam Thalamuthu, Karen Mather, Perminder S. Sachdev   +4 more
wiley   +1 more source

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens

Терапевтический архив, 2013
The paper gives the results of international trials of and guidelines for the use of maraviroc, the first CCR5 receptor antagonist, in treatment regimens for HIV-infected patients.
A V Kravchenko
doaj